Thomas C F, Tazelaar H D, Jett J R
Department of Medicine, Division of Pulmonary, Critical Care, and Internal Medicine, Mayo Clinic and Foundation, Rochester, MN 55905, USA.
Chest. 2001 Apr;119(4):1143-50. doi: 10.1378/chest.119.4.1143.
Typical pulmonary carcinoid tumors are well-differentiated neuroendocrine tumors that are associated with good patient survival rates, while atypical carcinoid tumors are more aggressive and have worse patient survival rates. Because these tumors rarely involve the thoracic lymph nodes at presentation, it is currently unknown to what extent the presence of thoracic lymph node metastases at the time of diagnosis influences patient survival.
A computerized search of the medical records for pulmonary carcinoid tumor at the Mayo Clinic from 1976 to 1997 revealed 517 patients, from which we identified 36 patients with pulmonary carcinoid tumors involving regional thoracic lymph nodes but without distant disease. For each patient, we reviewed the tumor histology, stage, and outcome. In addition, because the histologic criteria for the diagnosis of carcinoid tumors had changed significantly during the time of the study, we reexamined all of the histologic specimens using the current World Health Organization (WHO) criteria for classifying pulmonary neuroendocrine tumors.
After reclassification with the WHO criteria for neuroendocrine tumors, 23 patients had typical carcinoid tumors with thoracic lymph node involvement. At the last follow-up, 19 patients had no evidence of disease (NED), 2 patients had developed systemic metastases (SM) and are still alive, and 2 patients had died. Eleven patients had atypical carcinoid tumors with thoracic lymph node involvement. At the last follow-up, four patients had NED, seven patients had developed SM within a median time of 17 months, and six patients with SM died shortly thereafter (median survival time, 25.5 months), while one is still alive. Two patients had been reclassified with large cell neuroendocrine carcinoma at the time of this review; both of these patients had developed SM (at 4 months and 21 months after diagnosis) and had died (at 15 months and 21 months after diagnosis, respectively).
These data suggest that patients with atypical pulmonary carcinoid tumors with regional lymph node metastases have a high likelihood of developing recurrent disease if treated with surgical resection alone and have significantly worse outcome (p < 0.001) compared to those patients with typical carcinoid tumors with thoracic lymph node involvement.
典型肺类癌肿瘤是分化良好的神经内分泌肿瘤,患者生存率较高,而非典型类癌肿瘤侵袭性更强,患者生存率更低。由于这些肿瘤在初诊时很少累及胸段淋巴结,目前尚不清楚诊断时胸段淋巴结转移的存在在多大程度上影响患者生存率。
对梅奥诊所1976年至1997年期间肺类癌肿瘤的病历进行计算机检索,共发现517例患者,从中确定36例肺类癌肿瘤累及胸段区域淋巴结但无远处转移的患者。对每位患者的肿瘤组织学、分期和转归进行了回顾。此外,由于在研究期间类癌肿瘤的组织学诊断标准发生了显著变化,我们使用世界卫生组织(WHO)目前对肺神经内分泌肿瘤的分类标准重新检查了所有组织学标本。
根据WHO神经内分泌肿瘤标准重新分类后,23例患者为伴有胸段淋巴结受累的典型类癌肿瘤。在最后一次随访时,19例患者无疾病证据(NED),2例患者发生全身转移(SM)且仍存活,2例患者死亡。11例患者为伴有胸段淋巴结受累的非典型类癌肿瘤。在最后一次随访时,4例患者无疾病证据,7例患者在中位时间17个月内发生全身转移,6例发生全身转移的患者此后不久死亡(中位生存时间25.5个月),1例仍存活。在本次复查时,有2例患者被重新分类为大细胞神经内分泌癌;这2例患者均发生了全身转移(分别在诊断后4个月和21个月)并死亡(分别在诊断后15个月和21个月)。
这些数据表明,仅接受手术切除治疗的伴有区域淋巴结转移的非典型肺类癌肿瘤患者复发疾病的可能性很高,与伴有胸段淋巴结受累的典型类癌肿瘤患者相比,其转归明显更差(p<0.001)。